<DOC>
	<DOCNO>NCT02119286</DOCNO>
	<brief_summary>After screen , subject enter 4 week open-label run-in period fluticasone furoate ( FF ) /vilanterol ( VI ) 100/25 mcg administer daily via dry powder inhaler ( DPI ) . Subjects randomize receive one 3 treatment ( umeclidinium bromide [ UMEC ] [ 62.5 mcg ] administer daily via DPI ; OR UMEC [ 125 mcg ] administer daily via DPI ; OR match placebo administer daily via DPI ) , continue treatment open label FF/VI 100/25 mcg 12-week treatment period . There total eight schedule clinic visit Pre-Screening ( Visit0 ) , Screening ( Visit 1 ) , blind treatment Day 1 ( Visit2 ) , 2 ( Visit3 ) , 28 ( Visit4 ) , 56 ( Visit5 ) , 84 ( Visit6 ) 85 ( Visit7 ) . A follow-up phone contact conduct approximately 7 day last clinic visit . The total duration subject participation study Screening Follow-up approximately 17 week .</brief_summary>
	<brief_title>Study Compare Addition Umeclidinium Bromide ( UMEC ) Fluticasone Furoate ( FF ) /Vilanterol ( VI ) , With Placebo Plus FF/VI Subjects With Chronic Obstructive Pulmonary Disease ( COPD ) -Study 2</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Type subject : Outpatient . Informed Consent : A sign date write informed consent prior study participation . Age : Subjects 40 year age old Visit 1 . Gender : Male female subject . A female eligible enter participate study : Nonchild bear potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal surgically sterile ) . Surgically sterile female define documented hysterectomy and/or bilateral oophorectomy tubal ligation . Postmenopausal female define amenorrhoeic great 1 year appropriate clinical profile , e.g. , age appropriate , &gt; 45 year , absence hormone replacement therapy . OR Child bear potential , negative pregnancy test screening , agree one follow acceptable contraceptive method use consistently correctly ( i.e. , accordance approve product label instruction physician duration study screen followup contact ) : Abstinence Oral Contraceptive , either combined progestogen alone Injectable progestogen Implants levonorgestrel Estrogenic vaginal ring Percutaneous contraceptive patch Intrauterine device ( IUD ) intrauterine system ( IUS ) meet SOP effectiveness criterion state product label Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject . For definition , `` document '' refers outcome investigator's/designee 's medical examination subject review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record . Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) Diagnosis : An established clinical history COPD accordance definition American Thoracic Society/European Respiratory Society . Smoking History : Current former cigarette smoker history cigarette smoke &gt; =10 packyears [ number pack year = ( number cigarette per day / 20 ) x number year smoke ( e.g. , 20 cigarette per day 10 year , 10 cigarette per day 20 year ) ] . Former smoker define stop smoke least 6 month prior Visit 1 . Pipe and/or cigar use use calculate pack year history . Severity Disease : A pre postalbuterol/salbutamol FEV1/FVC ratio &lt; 0.70 pre postalbuterol/salbutamol FEV1 &lt; =70 % predict normal value Visit 1 ( Screening ) calculate use Nutrition Health Examination Survey ( NHANES ) III reference equation . Dyspnea : A score &gt; =2 mMRC Dyspnea Scale Visit 1 . QTc Criteria : QTc ( F ) &lt; 450 millisecond ( msec ) QTc ( F ) &lt; 480msec patient QRS duration &gt; =120msec The QTc QT interval correct heart rate accord either Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , another method , machine manual overread . For subject eligibility withdrawal , QTcF use . For purpose data analysis , QTcF use primary . The QTc base single average QTc value triplicate electrocardiogram ( ECGs ) obtain brief recording period . Pregnancy : Women pregnant lactate plan become pregnant study . Asthma : A current diagnosis asthma . Other Respiratory Disorders : Known alpha1 antitrypsin deficiency , active lung infection ( tuberculosis ) , lung cancer absolute exclusionary condition . A subject , opinion investigator , significant respiratory condition addition COPD exclude . Examples may include clinically significant bronchiectasis , pulmonary hypertension , sarcoidosis , interstitial lung disease . Other Diseases/Abnormalities : Subjects historical current evidence clinically significant cardiovascular , neurological , psychiatric , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality uncontrolled and/or previous history cancer remission &lt; 5 year prior Visit 1 ( localize carcinoma skin resect cure exclusionary ) . Significant defined disease , opinion investigator , would put safety subject risk participation , would affect efficacy safety analysis disease/condition exacerbate study . Contraindications : Any history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , beta2agonist , sympathomimetic , corticosteroid ( intranasal , inhaled systemic ) lactose/milk protein magnesium stearate , medical condition narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction , , opinion study physician contraindicates study participation use inhale Long act muscarinic antagonist ( LAMA ) , Long act beta agonist ( LABA ) Inhaled corticosteroid ( ICS ) . Hospitalization : Hospitalization COPD pneumonia within 12 week prior Visit 1 . Lower respiratory tract infection : Subjects low respiratory tract infection require use antibiotic within 6 week prior Visit 1 . Lung Resection : Subjects lung volume reduction surgery within 12 month prior Visit 1 . 12Lead ECG : An abnormal clinical significant ECG find 12lead ECG conduct Visit 1 . Investigators provide ECG review conduct centralized independent cardiologist assist evaluation subject eligibility . The study investigator determine medical significance ECG abnormality . Clinically significant abnormal laboratory find Screening ( Visit1 ) . After discussion Medical Monitor , investigator may option verify abnormal lab result prior Visit2 Medication Prior Spirometry : Unable withhold albuterol/salbutamol 4 hour period require prior spirometry test study visit . Excluded Medications : Use follow medication permit within defined time interval prior Visit 1and throughout study : No use within 12 week prior Screening Visit 1 thereafter time study : Depot corticosteroid . No use within 6 week prior Screening Visit 1 thereafter time study : Systemic , oral parenteral corticosteroid ( Intraarticular corticosteroid injection permit . ) , Antibiotics ( low respiratory tract infection ) , Cytochrome P450 3A4 strong inhibitor . No use within 14 day prior Screening Visit 1 thereafter time study : Phosphodiesterase 4 inhibitor ( roflumilast ) . No use within 10 day prior Screening Visit 1 thereafter time study : Olodaterol Indacaterol . No use within 7 day prior Screening Visit 1 thereafter time study : Long act muscarinici antagonist ( tiotropium , aclidinium , glycopyrronium ) . No use within 48 hrs prior Screening Visit 1 thereafter time study : Theophyllines , Oral leukotriene inhibitor ( zafirlukast , montelukast , zileuton ) , Salmeterol formoterol , ICS/LABA combination ( e.g. , fluticasone propionate/salmeterol , mometasone furoate/formoterol fumarate , budesonide/formoterol fumarate ) , Oral beta2agonists Longacting . No use within 24 hrs prior Screening Visit 1 thereafter time study : Inhaled sodium cromoglycate nedocromil sodium . No use within 12 hrs prior Screening Visit 1 thereafter time study : Oral beta2agonists Shortacting . No use within 4 hrs prior Screening Visit 1 thereafter time study : Inhaled short act beta2agonists ( use study provide prn albuterol/salbutamol permit study , except 4hour period prior spirometry test . ) , Inhaled shortacting anticholinergic , Inhaled shortacting anticholinergic/shortacting beta2agonist combination product . No use within 30 day 5 half life whichever longer prior Screening Visit 1 thereafter time study : Any investigational drug . Prior enrolment one replicate study : subject previously assign subject number ( enrol ) study 200110 replicate study 200109 . Oxygen : Use longterm oxygen therapy ( LTOT ) describe oxygen therapy prescribe great 12 hour day . Asneeded oxygen use ( i.e. , &lt; =12 hour per day ) exclusionary . Nebulized Therapy : Regular use ( prescribe use every day , asneeded use ) shortacting bronchodilator ( e.g. , albuterol/salbutamol ) via nebulized therapy . Pulmonary Rehabilitation Program : Participation acute phase pulmonary rehabilitation program within 4 week prior Visit 1 , enter acute phase pulmonary rehabilitation program study . Subjects maintenance phase pulmonary rehabilitation program exclude . Drug Alcohol Abuse : A know suspected history alcohol drug abuse within 2 year prior Visit 1 . Affiliation Investigator Site : A subject eligible study he/she immediate family member participate investigator , subinvestigator , study coordinator , employee participate investigator . Inability read : In opinion investigator , subject unable read and/or would able complete questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>long act beta2- receptor agonist</keyword>
	<keyword>long act muscarininc receptor antagonist</keyword>
	<keyword>dry powder inhaler</keyword>
	<keyword>safety</keyword>
	<keyword>COPD</keyword>
	<keyword>inhale corticosteroid</keyword>
	<keyword>efficacy</keyword>
	<keyword>fluticasone furoate/vilanterol</keyword>
	<keyword>umeclidinium bromide</keyword>
</DOC>